These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 11095447)

  • 41. Comparison of pathophysiology in subclinical hyperthyroidism with different etiologies.
    Deguchi-Horiuchi H; Ito M; Takahashi S; Kousaka K; Hisakado M; Fukata S; Kudo T; Nishihara E; Nishikawa M; Miyauchi A; Akamizu T
    Endocr J; 2024 Apr; 71(4):373-381. PubMed ID: 38296546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A pilot study on the beneficial effects of additional selenium supplementation to methimazole for treating patients with Graves’ disease.
    Xu B; Wu D; Ying H; Zhang Y
    Turk J Med Sci; 2019 Jun; 49(3):715-722. PubMed ID: 31023005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
    Siderova M; Hristozov K; Tsukeva A
    Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting the Relapse of Hyperthyroidism in Treated Graves' Disease with Orbitopathy by Serial Measurements of TSH-Receptor Autoantibodies.
    Stöhr M; Oeverhaus M; Lytton SD; Horstmann M; Zwanziger D; Möller L; Stark A; Führer-Sakel D; Bechrakis N; Berchner-Pfannschmidt U; Banga JP; Philipp S; Eckstein A
    Horm Metab Res; 2021 Apr; 53(4):235-244. PubMed ID: 33618407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
    Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
    Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of administration of thyroxine on the risk of postpartum recurrence of hyperthyroid Graves' disease.
    Hashizume K; Ichikawa K; Nishii Y; Kobayashi M; Sakurai A; Miyamoto T; Suzuki S; Takeda T
    J Clin Endocrinol Metab; 1992 Jul; 75(1):6-10. PubMed ID: 1642700
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 2013 European survey of clinical practice patterns in the management of Graves' disease.
    Bartalena L; Burch HB; Burman KD; Kahaly GJ
    Clin Endocrinol (Oxf); 2016 Jan; 84(1):115-20. PubMed ID: 25581877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal iodine supplementation during antithyroid drug therapy for Graves' disease is associated with lower recurrence rates than iodine restriction.
    Huang H; Shi Y; Liang B; Cai H; Cai Q; Lin R
    Clin Endocrinol (Oxf); 2018 Mar; 88(3):473-478. PubMed ID: 29288501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating Levels of Orexin-A, Nesfatin-1, Agouti-Related Peptide, and Neuropeptide Y in Patients with Hyperthyroidism.
    Tohma Y; Akturk M; Altinova A; Yassibas E; Cerit ET; Gulbahar O; Arslan M; Sanlier N; Toruner F
    Thyroid; 2015 Jul; 25(7):776-83. PubMed ID: 25915725
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds.
    Zhyzhneuskaya S; Addison C; Tsatlidis V; Weaver JU; Razvi S
    Thyroid; 2016 Jun; 26(6):765-9. PubMed ID: 27090092
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study.
    Wang X; Li T; Li Y; Wang Q; Cai Y; Wang Z; Shi Y; Yang T; Zheng X
    J Transl Med; 2024 Mar; 22(1):318. PubMed ID: 38553734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of Early-Pregnancy Antithyroid Drug Withdrawal in Graves' Disease: A Preliminary Prospective Follow-Up Study.
    Hou X; Guan H; Sun S; Shi Y; Li C; Liu A; Li Y; Gao X; Hou Y; Yang Y; Li Y; Shan Z; Teng W
    Thyroid; 2022 Aug; 32(8):983-989. PubMed ID: 35651276
    [No Abstract]   [Full Text] [Related]  

  • 53. Changes in serum TSH and T4 after T3 suppression tests in patients treated for hyperthyroidism due to Graves' disease.
    Suematsu H; Tamai H; Esaki M; Kurokawa N; Aoki H; Matsuzuka F; Miyauchi A; Kuma K
    J Clin Endocrinol Metab; 1977 Nov; 45(5):1013-8. PubMed ID: 579181
    [No Abstract]   [Full Text] [Related]  

  • 54. Thyroid function test variability and cardiovascular morbidity in hyperthyroidism.
    Suonsyrjä N; Laihia I; Huhtala H; Jaatinen P; Metso S
    Clin Endocrinol (Oxf); 2023 Oct; 99(4):428-436. PubMed ID: 37497807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A SURVEY OF CLINICAL PRACTICE PATTERNS IN MANAGEMENT OF GRAVES DISEASE IN THE MIDDLE EAST AND NORTH AFRICA.
    Beshyah SA; Khalil AB; Sherif IH; Benbarka MM; Raza SA; Hussein W; Alzahrani AS; Chadli A
    Endocr Pract; 2017 Mar; 23(3):299-308. PubMed ID: 27967219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical significance of thyroglobulin antibodies and thyroid peroxidase antibodies in Graves' disease: a cross-sectional study.
    Katahira M; Tsunekawa T; Mizoguchi A; Yamaguchi M; Tsuru K; Takashima H; Terada R
    Hormones (Athens); 2023 Jun; 22(2):253-261. PubMed ID: 36811756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Decreased serum interleukin-41/Metrnl levels in patients with Graves' disease.
    Gong L; Huang G; Weng L; Xu J; Li Y; Cui W; Li M
    J Clin Lab Anal; 2022 Oct; 36(10):e24676. PubMed ID: 36036749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study.
    Li C; Tan J; Zhang G; Meng Z; Wang R; Li W; Zheng W
    Horm Metab Res; 2015 Mar; 47(3):209-13. PubMed ID: 24867136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High Titers of Thyrotropin Receptor Antibodies Are Associated With Orbitopathy in Patients With Graves Disease.
    Kahaly GJ; Wüster C; Olivo PD; Diana T
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2561-2568. PubMed ID: 30753531
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Follow-Up of Thyroid Function in Children With Neonatal Hyperthyroidism.
    Pyrżak B; Rumińska M; Witkowska-Sędek E; Kucharska A
    Front Endocrinol (Lausanne); 2022; 13():877119. PubMed ID: 35600602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.